Principal Scientist Ii
Currento Lead, developed and performed studies designed to elucidate target biology in vitro and in vivo in order to stratify patient populations, identify pharmacodynamic markers for potential clinical assays, and identify nodes of resistance/synergy/synthetic lethalityo Utilized genetic (CRISPR-Cas9/siRNA/shRNA/cDNA over-expression) means along with genomic/transcriptional/epigenetic/metabolic profiling and analysis in order to validate a number of potential cancer targets across numerous cancer typeso Developed a range of cellular assays to screen/identify small molecule inhibitors in the hit-to-lead or lead optimization phases for on and off target dependencieso Contributed to the validation, biomarker identification, assay development, lead selection, and mechanism of action studies that lead to the IND filing for IDH305, a mutant specific small molecule inhibitor of IDH1, which achieved POC in AML. o Proficient in mammalian cell culture (adherent, suspension, spheroid), lentiviral/retroviral transduction, range of cell proliferation assays, metabolic profiling, histone modification detection, DNA methylation profiling, nucleic acid isolation and QC, RNA-seq & follow-up analysis, immunoblotting, immunoprecipitation, qRT-PCR, DNA cloning, site-directed mutagenesis.o Contributed to an Accelerate Brain Cancer Cure (ABC2) funded collaboration with the Henry Ford Hospital and Columbia Universityo Mentored a Summer Scholar student (2017) and a Post-baccalaureate Scholar student (2017-2019)
